Sequence analysis of HIV-1 isolates from Guinea-Bissau: Selection of vaccine epitopes relevant in both West African and European countries

APMIS

Volumn 119, Issue 8, 2011, Pages 487-497

  Vinner, Lasse ^a   Holmgren, Birgitta ^b   Jensen, Kristoffer J ^a   Esbjornsson, Joakim ^c   Borggren, Marie ^b   Hentze, Julie L ^a   Karlsson, Ingrid ^a   Andresen, Betina S ^a   Gram, Gregers J ^a   Kloverpris, Henrik ^a   Aaby, Peter ^d   Da Silva, Zacarias José ^d   Fenyö, Eva Maria ^b   Fomsgaard, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

Author keywords

CD8 epitopes; Guinea Bissau; HIV 1 vaccine

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINE;

ADULT; ALLELE; AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; ENVELOPE GENE; GENE CLUSTER; GENE SEQUENCE; GENOTYPE; GLYCOSYLATION; GUINEA-BISSAU; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PRIORITY JOURNAL; STRUCTURAL GENE; TROPISM; VACCINATION; VIRUS CHARACTERIZATION; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

AIDS VACCINES; BASE SEQUENCE; DENMARK; EPITOPES, T-LYMPHOCYTE; GUINEA-BISSAU; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ALIGNMENT; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79960283842     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02763.x     Document Type: Article

References (51)

1. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008;22:1195-202.
2. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006;24:227-55.
3. Thorn M, Tang S, Therrien D, et al. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 2007;115:757-68.
4. Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006;7:173-8.
5. Kloverpris H, karlsson I, Bonde J, et al. Induction of novel CD8(+) T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009;23:1329-40.
6. Oukka M, Manuguerra JC, Livaditis N, et al. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 1996;157:3039-45.
7. Tourdot S, Oukka M, Manuguerra JC, et al. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J Immunol 1997;159:2391-8.
8. del Guercio MF, Sidney J, Hermanson G, et al. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995;154:685-93.
9. Sidney J, Southwood S, del Guercio MF, et al. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. J Immunol 1996;157:3480-90.
10. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008;9:1.
11. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999;50:201-12.
12. Lund O, Nielsen M, Kesmir C, et al. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 2004;55: 797-810.
13. Spinola C, Bruges-Armas J, Brehm A, Spinola H. HLA-A polymorphisms in four ethnic groups from Guinea-Bissau (West Africa) inferred from sequence-based typing. Tissue Antigens 2008; 72:593-8.
14. Perez CL, Larsen MV, Gustafsson R, et al. Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol 2008;180:5092-100.
15. Corbet S, Nielsen HV, Vinner L, et al. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J Gen Virol 2003;84:2409-21.
16. Zhang QJ, Gavioli R, Klein G, Masucci MG. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci USA 1993;90:2217-21.
17. Reche PA, Keskin DB, Hussey RE, Ancuta P, Gabuzda D, Reinherz EL. Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes. Med Immunol 2006;5:1.
18. Day CL, Shea AK, Altfeld MA, et al. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J Virol 2001;75:6279-91.
19. Sabbaj S, Bansal A, Ritter GD, et al. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J Acquir Immune Defic Syndr 2003;33:426-38.
20. Frahm N, Yusim K, Suscovich TJ, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007;37:2419-33.
21. Costa CI, Morgado MG, Santos VG, Bongertz V. HIV-1 isolation from plasma specimens HEC/FIOCRUZ AIDS Clinical Research Group. Mem Inst Oswaldo Cruz 1996;91:745-6.
22. Rousseau CM, Birditt BA, McKay AR, et al. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods 2006;136:118-25.
23. Andresen BS, Vinner L, Tang S, et al. Characterization of near full-length genomes of HIV type 1 strains in Denmark: basis for a universal therapeutic vaccine. AIDS Res Hum Retroviruses 2007;23:1442-8.
24. Antonsson L, Boketoft A, Garzino-Demo A, Olde B, Owman C. Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. AIDS 2003;17:2571-9.
25. karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003;17:2561-9.
26. Fenyo EM, Heath A, Dispinseri S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009;4:e4505.
27. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-60.
28. Fernandez-Garcia A, Cuevas MT, Munoz-Nieto M, et al. Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses 2009;1:93-102.
29. Andersson S, Norrgren H, Dias F, Biberfeld G, Albert J. Molecular characterization of human immunodeficiency virus (HIV)-1 and-2 in individuals from Guinea-Bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. Virology 1999;262:312-20.
30. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-W23.
31. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007;81:10209-19.
32. Jacobs GB, Loxton AG, Laten A, Engelbrecht S. Complete genome sequencing of a non-syncytium-inducing HIV type 1 subtype D strain from Cape Town, South Africa. AIDS Res Hum Retroviruses 2007;23:1575-8.
33. Luk KC, Holzmayer V, Yamaguchi J, et al. Near full-length genome characterization of three additional HIV type 1 CRF13-cpx strains from Cameroon. AIDS Res Hum Retroviruses 2007;23:297-302.
34. Fang G, Kuiken C, Weiser B, et al. Long-term survivors in Nairobi: complete HIV-1 RNA sequences and immunogenetic associations. J Infect Dis 2004;190:697-701.
35. Harris ME, Serwadda D, Sewankambo N, et al. Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 2002;18:1281-90.
36. Montavon C, Toure-Kane C, Liegeois F, et al. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr 2000;23:363-74.
37. Kijak GH, Sanders-Buell E, Wolfe ND, et al. Development and application of a high-throughput HIV type 1 genotyping assay to identify CRF02-AG in West/West Central Africa. AIDS Res Hum Retroviruses 2004;20:521-30.
38. Toure-Kane C, Montavon C, Faye MA, et al. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res Hum Retroviruses 2000;16:603-9.
39. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005;21:171-89.
40. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006;80:750-8.
41. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994;32:364-70.
42. Karlsson I, Antonsson L, Shi Y, et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004;78:11807-15.
43. Lauren A, Vodros D, Thorstensson R, Fenyo EM. Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): evolution of coreceptor use varies with pathogenic outcome. J Gen Virol 2006;87:581-94.
44. Garrido C, Roulet V, Chueca N, et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008;46:887-91.
45. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14:617-21.
46. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008;321:530-2.
47. Jorgensen LB, Christensen MB, Gerstoft J, et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003;35:800-7.
48. Spinola H, Bruges-Armas J, Middleton D, Brehm A. HLA polymorphisms in Cabo Verde and Guine-Bissau inferred from sequence-based typing. Hum Immunol 2005;66:1082-92.
49. Buus S, Lauemoller SL, Worning P, et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003;62:378-84.
50. Leslie A, Price DA, Mkhize P, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 2006;177:4699-708.
51. Tanigaki N, Fruci D, Chersi A, Falasca G, Tosi R, Butler RH. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Hum Immunol 1994;39:155-62.